Unsere Publikationenund Kongressbeiträge
In diesem Bereich sind neuere Publikationen gelistet. Für ältere Publikationen kontaktieren Sie uns bitte oder besuchen Sie die PubMed Website (PubMed (nih.gov))
In Vitro Activity of Cefiderocol against a Global Collection of Carbapenem-Resistant Acinetobacter baumannii Isolates.
Seifert H, Müller C, Stefanik D, Higgins PG, Wohlfarth E, Kresken M.Antibiotics (Basel). 2023 Jul 11;12(7):1172. doi: 10.3390/antibiotics12071172.
In Vitro Activity of Cefiderocol against Clinical Gram-Negative Isolates Originating from Germany in 2016/17.
Wohlfarth E, Kresken M, Deuchert F, Gatermann SG, Pfeifer Y, Pfennigwerth N, Seifert H, Higgins PG, Werner G, Study Group ‘Antimicrobial Resistance’ Of The Paul Ehrlich Society For Infection Therapy.Antibiotics (Basel). 2023 May 6;12(5):864. doi: 10.3390/antibiotics12050864.
Susceptibility of Multidrug-Resistant Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa from Germany to Ceftolozane-Tazobactam, Ceftazidime-Avibactam, and Imipenem-Relebactam.
Kresken M, Wohlfarth E, Wichelhaus TA, Gatermann SG, Pfennigwerth N, Eisfeld J, Seifert H; German BL/BLI Study Group.Microb Drug Resist. 2023 Apr;29(4):138-144. doi: 10.1089/mdr.2022.0175.
Resistance to Mecillinam and Nine Other Antibiotics for Oral Use in Escherichia coli Isolated from Urine Specimens of Primary Care Patients in Germany, 2019/20.
Kresken M, Pfeifer Y, Wagenlehner F, Werner G, Wohlfarth E, Therapy OBOSG’ROTPESFI.Antibiotics (Basel). 2022 May 31;11(6):751. doi: 10.3390/antibiotics11060751.
The evolution of carbapenem resistance determinants and major epidemiological lineages among carbapenem-resistant Acinetobacter baumannii isolates in Germany, 2010-2019.
Wohlfarth E, Kresken M, Higgins PG, Stefanik D, Wille J, Hafner D, Körber-Irrgang B, Seifert H; Study Group “Antimicrobial Resistance” of the Paul-Ehrlich-Society for Infection Therapy.Int J Antimicrob Agents. 2022 Nov-Dec;60(5-6):106689. doi: 10.1016/j.ijantimicag.2022.106689.
In vitro activity of gepotidacin against urine isolates of Escherichia coli from outpatient departments in Germany.
Kresken M, Wohlfarth E, Weikel C, Butler D, Pfeifer Y, Werner G; ‘Antimicrobial Resistance’ Study Group of the Paul Ehrlich Society for Infection Therapy.J Antimicrob Chemother. 2022 Dec 7:dkac406. doi: 10.1093/jac/dkac406.
Multicenter Clinical Evaluation of ETEST Plazomicin (PLZ) for Susceptibility Testing of Enterobacterales – PubMed (nih.gov)
Blanchard L, Belkum A, Dechaume D, Armstrong T, Emery C, Ying Y, Kresken M, Pompilio M, Halimi D, Zambardi G
Kresken M, Pfeifer Y, Wagenlehner F, Werner G, Wohlfarth E; on behalf of Study Group ‘Antimicrobial Resistance‘ of the Paul Ehrlich Society for Infection Therapy. Resistance to Mecillinam and Nine Other Antibiotics for Oral Use in Escherichia coli Isolated from Urine Specimens of Primary Care Patients in Germany, 2019/20. Antibiotics 2022, 11, 751. https://doi.org/10.3390/antibiotics11060751
Study Group ‘Antimicrobial Resistance’ of the Paul-Ehrlich-Society for Chemotherapy. Glycopeptide resistance in Enterococcus spp. and coagulase-negative staphylococci from hospitalised patients in Germany: occurrence, characteristics and dalbavancin susceptibility. J Glob Antimicrob Resist. 2022 Mar;28:102-107. doi: 10.1016/j.jgar.2021.12.016.
Kresken M, Klare I, Wichelhaus TA, Wohlfarth E, Layer-Nicolaou F, Neumann B, Werner G
Kresken M, Pfeifer Y, Werner G. Comparative in vitro activity of piperacillin-tazobactam and temocillin against third-generation cephalosporin-resistant, carbapenem-susceptible Escherichia coli and Klebsiella pneumoniae. GMS Infect Dis 2021; 9:Doc08 (20211221). https://doi.org/10.3205/id000077
Study Group ‘Antimicrobial Resistance’ of the Paul-Ehrlich-Society for Chemotherapy. Glycopeptide resistance in Enterococcus spp. and coagulase-negative staphylococci from hospitalized patients in Germany: occurrence, characteristics, and susceptibility to dalbavancin. J Glob Antimicrob Resist. 2021 Dec 24:S2213-7165(21)00289-7
Kresken M, Klare I, Wichelhaus TA, Wohlfarth E, Layer-Nicolaou F, Neumann B, Werner G
Determination of a Tentative Epidemiological Cut-Off Value (ECOFF) for Dalbavancin and Enterococcus faecium. Antibiotics 2021, 10(8), 915
Weber RE, Fleige C, Layer F, Neumann B, Kresken M, Werner, G
In vitro activity of ceftazidime/avibactam against ceftazidime-resistant Enterobacterales and Pseudomonas aeruginosa from hospitalised patients in Germany. J Global Antimicrob Resist. 2021;25: 337–338
Kresken M, Korte-Berwanger M, Pfennigwerth N, Gatermann SG.
Evaluation of a Phenotypic Algorithm to Direct Carbapenemase Testing in Pseudomonas aeruginosa: Validation in a Multicenter German Cohort. Microb Drug Resist. 20121; 27: 1243–1248.
Gill CM, Kresken M, Seifert H, Nicolau DP.
Die veränderte Definition von SIR bei Empfindlichkeitstestungen nach EUCAST.Krankenhaushygiene up2date 2020; 15: 395–403
Gatermann S, Hamprecht A, Kresken M.
The VRE study group. Thirty years of VRE in Germany – “expect the unexpected”: The view from the National Reference Centre for Staphylococci and Enterococci. Drug Resist Updat 53 (2020) 100732
Werner G, Neumann B, Weber RE, Kresken M, Wendt C, Bender JK.
Temocillin susceptibility in Enterobacterales with an ESBL/AmpC-phenotype. Int J Antimicrob Agents. 2020; In Press, Journal Pre-proof, Available online 7 November 2020.
Kresken M, Pfeifer Y, Werner G.
In vitro activity of cefiderocol against aerobic Gram-negative bacterial pathogens from Germany. Int J Antimicrob Agents. 2020; 56:106128.
Kresken M, Korte-Berwanger M, Gatermann SG, Pfeifer Y, Pfennigwerth N, Seifert H, Werner G.
In vitro activity of sulbactam/durlobactam against global isolates of carbapenem-resistant Acinetobacter baumannii. J Antimicrob Chemother 2020;75(9):2616–2621.
Seifert H, Müller C, Stefanik D, Higgins PG, Miller A, Kresken M. https://doi.org/10.1093/jac/dkaa208folgende
The phylogenetic landscape and nosocomial spread of the multidrug-resistant opportunist Stenotrophomonas maltophilia. Nat Commun. 2020 Apr 27;11(1):2044. doi: 10.1038/s41467-020-15123-0.
Gröschel MI, Meehan CJ, Barilar I, Diricks M, Gonzaga A, Steglich M, Conchillo-Solé O, Scherer IC, Mamat U, Luz CF, De Bruyne K, Utpatel C, Yero D, Gibert I, Daura X, Kampmeier S, Rahman NA, Kresken M, van der Werf TS, Alio I, Streit WR, Zhou K, Schwartz T, Rossen JWA, Farhat MR, Schaible UE, Nübel U, Rupp J, Steinmann J, Niemann S, Kohl TA.
Dissemination of carbapenem-resistant Pseudomonas aeruginosa isolates and their susceptibilities to ceftolozane-tazobactam in Germany. Int J Antimicrob Agents. 2020; 55(6): 105959 doi: 10.1016/j.ijantimicag.2020.105959.
Kresken M, Körber-Irrgang B, Korte-Berwanger M, Pfennigwerth N, Gatermann SG, Seifert H; German Carbapenem Resistance Study Group.
Guideline Calculated parenteral initial therapy. Calculated parenteral initial treatment of bacterial infections: Introduction and antibiotics. GMS Infect Dis 2020; 8:Doc19 (20200326).
Bodmann KF, Kresken M, Grabein B, Dohmen PM, Wilke M.
Guideline Calculated parenteral initial therapy. Calculated parenteral initial treatment of bacterial infections: Microbiology. GMS Infect Dis 2020; 8:Doc18 (20200326)
Kresken M, Grabein B, Becker K, Straube E, Wichelhaus TA, Willinger B.
Antibiotic resistance in Haemophilus influenzae isolates obtained from patients at outpatient departments in Germany, 2019/2020. 32nd European Congress of Clinical Microbiology and Infectious Diseases
Lâm TT, Wohlfarth E, Claus H, Vogel C, Kresken M. Antibiotic resistance in Haemophilus influenzae isolates obtained from patients at outpatient departments in Germany, 2019/2020. 32nd European Congress of Clinical Microbiology and Infectious Diseases, Lisbon / Online, 23-26 April 2022. Oral Session OF094, Abstract 537, Talk O0394
Treatment patterns and outcomes among females with uncomplicated urinary tract infection in Germany: a physician-based chart review. 32nd European Congress of Clinical Microbiology and Infectious Diseases
Wagenlehner F, Kresken M, Naber K, Cheng WY, Catillon M, Mulgirigama A, Duh MS, Yu L, Khanal A, Joshi AV, Ju S, Mitrani-Gold FS. Treatment patterns and outcomes among females with uncomplicated urinary tract infection in Germany: a physician-based chart review. 32nd European Congress of Clinical Microbiology and Infectious Diseases, Lisbon / Online, 23-26 April 2022. Poster Session PS012, Abstract 657, Poster P0346
Antimicrobial resistance patterns and patient characteristics among females with uncomplicated urinary tract infection in Germany: a physician-based chart review. 32nd European Congress of Clinical Microbiology and Infectious Diseases
Naber K, Kresken M, Wagenlehner F, Cheng WY, Catillon M, Mulgirigama A, Duh MS, Yu L, Khanal A, Joshi AV, Ju S, Mitrani-Gold FS. Antimicrobial resistance patterns and patient characteristics among females with uncomplicated urinary tract infection in Germany: a physician-based chart review. 32nd European Congress of Clinical Microbiology and Infectious Diseases, Lisbon / Online, 23-26 April 2022. Poster Session PS018, Abstract 655, Poster P0595
Comparative in-vitro activity of cefiderocol and four newer β-lactam/β-lactamase inhibitor combinations against two panels of clinically important Gramnegative pathogens from Germany. 32nd European Congress of Clinical Microbiology and Infectious Diseases
Kresken M, Gatermann SG, Higgins PG, Pfeifer Y, Pfennigwerth N, Seifert H, Werner G, Wohlfarth E. Comparative in-vitro activity of cefiderocol and four newer β-lactam/β-lactamase inhibitor combinations against two panels of clinically important Gramnegative pathogens from Germany. 32nd European Congress of Clinical Microbiology and Infectious Diseases, Lisbon / Online, 23-26 April 2022. Poster Session PS018, Abstract 629, Poster P0599
In vitro activity of gepotidacin against urine isolates of Escherichia coli from outpatient departments in Germany. 32nd European Congress of Clinical Microbiology and Infectious Diseases
Kresken M, Wohlfarth E, Weikel C, Butler D, Pfeifer Y, Werner G. In vitro activity of gepotidacin against urine isolates of Escherichia coli from outpatient departments in Germany. 32nd European Congress of Clinical Microbiology and Infectious Diseases, Lisbon / Online, 23-26 April 2022. Poster Session PS018, Abstract 60, Poster P0686
Highly conserved mcr-1-carrying plasmids but polyclonal spread of colistin-resistant Escherichia coli from human patients and livestock products in Germany. 32nd European Congress of Clinical Microbiology and Infectious Diseases
Neumann B, Rackwitz W, Pfennigwerth N, Hunfeld K-P, Kresken M, Leistner R, Probst-Kepper M, Hammerl JA, Werner G, Pfeifer Y. Highly conserved mcr-1-carrying plasmids but polyclonal spread of colistin-resistant Escherichia coli from human patients and livestock products in Germany. 32nd European Congress of Clinical Microbiology and Infectious Diseases, Lisbon / Online, 23-26 April 2022. Poster Session PS020, Abstract 1494, Poster P0840
Detection of carbapenemases in Enterobacterales: presentation of the new German guideline. 32nd European Congress of Clinical Microbiology and Infectious Diseases
Hamprecht A, Kresken M, Mack D, Molitor E, Gatermann S. Detection of carbapenemases in Enterobacterales: presentation of the new German guideline. 32nd European Congress of Clinical Microbiology and Infectious Diseases, Lisbon / Online, 23-26 April 2022. Poster Session PS021, Abstract 2280, Poster P0864
In vitro activity of ceftolozane/tazobactam against Enterobacterales and Pseudomonas aeruginosa isolates obtained from patients with hospital-acquired pneumonia in Germany.
Kresken M, Körber-Irrgang B, Korte-Berwanger M, Pfennigwerth N, Gatermann SG, Wohlfarth E, Seifert H. In vitro activity of ceftolozane/tazobactam against Enterobacterales and Pseudomonas aeruginosa isolates obtained from patients with hospital-acquired pneumonia in Germany. 31st European Congress of Clinical Microbiology and Infectious Diseases, Online, 9-12 July 2021, ePoster, Abstract No. 395
Multidrug resistance in Escherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa and susceptibility to four last resort antimicrobials, Germany.
Kresken M, Wohlfarth E, Wichelhaus TA, Gatermann SG, Seifert H. Multidrug resistance in Escherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa and susceptibility to four last resort antimicrobials, Germany. 31st European Congress of Clinical Microbiology and Infectious Diseases, Online, 9-12 July 2021, ePoster, Abstract No. 443
Genome-based characterisation of colistin-resistant Escherichia coli isolates from human patients and livestock products in Germany.
Rackwitz W, Neumann B, Pfennigwerth N, Hunfeld KP, Kresken M, Leistner R, Probst-Kepper M, Fuchs S, Werner G, Pfeifer Y. Genome-based characterisation of colistin-resistant Escherichia coli isolates from human patients and livestock products in Germany. 31st European Congress of Clinical Microbiology and Infectious Diseases, Online, 9-12 July 2021, ePoster, Abstract No. 2164
Determination of a dalbavancin epidemiological cut-off value (ECOFF) for Enterococcus faecium.
Weber R, Fleige C, Layer F, Neumann B, Kresken M, Werner G. Determination of a dalbavancin epidemiological cut-off value (ECOFF) for Enterococcus faecium. 31st European Congress of Clinical Microbiology and Infectious Diseases, Online, 9-12 July 2021, ePoster, Abstract No. 4385
In vitro activity of dalbavancin against glycopeptide-resistant Enterococcus faecium and coagulase-negative staphylococci recovered from patients in Germany.
Kresken M, Klare I, Wichelhaus TA, Wohlfarth E, Werner G. In vitro activity of dalbavancin against glycopeptide-resistant Enterococcus faecium and coagulase-negative staphylococci recovered from patients in Germany. 31st European Congress of Clinical Microbiology and Infectious Diseases, Online, 9-12 July 2021, Oral Session, Abstract No. 393
The evolution of carbapenem resistance determinants and major epidemiological lineages among carbapenem-resistant Acinetobacter baumannii isolates in Germany
Wohlfarth E, Kresken M, Higgins P, Stefanik D, Wille J, Körber-Irrgang B, Seifert H. The evolution of carbapenem resistance determinants and major epidemiological lineages among carbapenem-resistant Acinetobacter baumannii isolates in Germany, 2010-2019. 31st European Congress of Clinical Microbiology and Infectious Diseases, Online, 9-12 July 2021, Oral Session, Abstract No. 4821
The phylogenetic landscape and nosocomial spread of the multidrug-resistant opportunist Stenotrophomonas maltophilia.
M. Groschel, C. Meehan, I. Barilar, M. Diricks, A. Gonzaga, M. Steglich, O. Conchillo-Sole, I. Scherer, U. Mamat, C. Luz, K. De Bruyne, C. Utpatel, D. Yero, I. Gibert, X. Daura, S. Kampmeier, N. Abdul Rahman, M. Kresken, T. Van Der Werf, I. Alio, W. Streit, K. Zhou, T. Schwartz, J. Rossen, U. Schaible, M. Farhat, U. Nübel, J. Rupp, J. Steinmann, S. Niemann, T. Kohl. The phylogenetic landscape and nosocomial spread of the multidrug-resistant opportunist Stenotrophomonas maltophilia. 30th European Congress of Clinical Microbiology and Infectious Diseases, 2020, Abstract Book: Abstract 48, p. 259.
Eravacycline for antimicrobial susceptibility testing of Enterobacteriaceae and Enterococcus spp.: performance results from a multi-centre study.
L. Blanchard, T. Armstrong, D. Gerald, Y. Ying, M. Kresken, J. Carpenter, V. Sauvonnet, G. Zambardi. Eravacycline for antimicrobial susceptibility testing of Enterobacteriaceae and Enterococcus spp.: performance results from a multi-centre study. 30th European Congress of Clinical Microbiology and Infectious Diseases, 2020, Abstract Book: Abstract 1079, p. 566.
In vitro activity of ceftazidime/avibactam against ceftazidime-resistant Enterobacterales and Pseudomonas aeruginosa from hospitalised patients in Germany
M. Kresken, M. Korte-Berwanger, N. Pfennigwerth, S. Gatermann. In vitro activity of ceftazidime/avibactam against ceftazidime-resistant Enterobacterales and Pseudomonas aeruginosa from hospitalised patients in Germany: 2016-17. 30th European Congress of Clinical Microbiology and Infectious Diseases, 2020, Abstract Book: Abstract 1089, p. 568.
Genome-based surveillance of clinical vancomycin-resistant Enterococcus faecium reveals increased prevalence of vanB-type isolates of ST117/CT71 in German hospitals
B. Neumann, M. Kresken, G. Werner. Genome-based surveillance of clinical vancomycin-resistant Enterococcus faecium reveals increased prevalence of vanB-type isolates of ST117/CT71 in German hospitals, 2010-2016. 30th European Congress of Clinical Microbiology and Infectious Diseases, 2020, Abstract Book: Abstract 1735, p. 839.